ADVANCING IMMUNO-ONCOLOGY

Management

Interim CEO, President, and General Counsel

Frederick G. Vogt, PhD, JD

Dr. Fred Vogt joined Iovance in September 2016. He has more than 20 years of experience in the pharmaceutical and biopharmaceutical industries. Prior to joining Iovance, he practiced law at the international firm of Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy, transactional, and litigation matters. Previously he served in numerous scientific, management, and legal roles of increasing responsibility over a period of 13 years at GlaxoSmithKline, where he focused primarily on oncology and cardiovascular drug development. Fred holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from the Pennsylvania State University, and a J.D. from Temple University. He has authored or co-authored more than 70 research papers and book chapters and is a co-inventor of numerous patent applications in the drug development and life sciences fields. He is admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office and the U.S. District Court for the Eastern District of Pennsylvania.

Chief Medical Officer

Friedrich Graf Finckenstein, MD

Dr. Friedrich Graf Finckenstein joined Iovance in July 2019. He is a physician-scientist with decades of experience in clinical medicine, laboratory cancer research, and drug development in the biopharmaceutical industry. Prior to joining Iovance he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland, where he led all clinical development aspects in the Oncology Discovery and Translational Area, including the design and conduct of clinical trials, exploratory development studies and translational medicine, biomarker and personalized healthcare strategy. Earlier Friedrich held multiple clinical leadership roles at Bristol-Myers Squibb, where he worked on an array of products from early to late-stage clinical development, including key contributions to the approval of Opdivo® in lung cancer. Friedrich has a medical degree from the University of Hamburg in Germany. He holds a German medical license, a pediatric board certification, and has conducted basic cancer research at the Ludwig Institute for Cancer Research San Diego Branch, the Children’s Hospital Los Angeles, and the University of Hamburg.

Chief Financial Officer

Jean-Marc Bellemin, MBA

Jean-Marc Bellemin joined Iovance in December 2020. Previously he served as Executive Vice President of Finance and Chief Financial Officer at Gritstone Oncology, a publicly traded company developing cancer immunotherapies. Prior to Gritstone, Jean-Marc served as Senior Vice President, Market Access, Business Solutions and Services at Actelion Pharmaceuticals US Inc., or Actelion, a biotechnology company, until Actelion was acquired by Johnson & Johnson. Prior to Actelion, Jean-Marc held several financial leadership roles at Guerbet Group. Mr. Bellemin received a degree in Economics and a Master’s in Finance from Université Paris Dauphine, a postgraduate degree in Finance and Accounting from Université Paris II Panthéon-Sorbonne and an M.B.A. from the ESSEC Business School in Paris, France.

Chief Operating Officer

Igor Bilinsky, PhD

Dr. Igor Bilinsky joined Iovance in March 2021. He has more than 20 years of cumulative leadership experience through prior roles as Chief Executive Officer, Chief Operating Officer, and Chief Business Officer at companies within the life sciences industry. Prior to joining Iovance, he served as Chief Business Officer of Oncternal Therapeutics, where he was integral in building the publicly traded oncology company. Previously, Igor served as Chief Operating Officer of AmpliPhi Biosciences and as General Manager of Immuno-oncology and Senior Vice President at Ignyta (now part of Roche). His prior experience also includes senior executive roles at Vical and Halozyme Therapeutics, and Chief Executive Officer at Androclus Therapeutics. He also served as a principal in the healthcare practice of Boston Consulting Group. Igor received a B.S. in physics from the Moscow Institute of Physics and Technology and a Ph.D. in physics from the Massachusetts Institute of Technology.

Chief Business Officer

Howard B. Johnson, MBA

Howard B. Johnson joined Iovance in August 2015 and was promoted to Chief Business Officer in March 2019. He currently leads corporate development and alliance management. Howard is an entrepreneurial executive with more than 30 years of experience in operations, finance, business development, investor relations and venture capital, primarily in bioscience companies. Prior to Iovance, he held executive roles at public and private companies including President and Chief Financial Officer at Vion Pharmaceuticals, an oncology drug development company. He was also a founding investor and initial board member of Acorda Therapeutics. Earlier in his career, Howard was an investment banker working on product development financings for leading biotech companies. He received a B.A. from Harvard College and an M.B.A. from Harvard Business School.

Executive Vice President, Regulatory Strategy and Translational Medicine

Raj. K. Puri, MD, PhD

Dr. Raj Puri joined Iovance in March 2022. He has decades of experience with the evaluation and regulation of advanced therapies, including cell and gene therapy, cancer vaccines and cellular immunotherapy. Raj previously spent 33 years working at the U.S. FDA, including more than 19 years as the Director of the Division of Cellular and Gene Therapies (DCGT) in the Office of Tissues and Advanced Therapies in the Center for Biologics Evaluation and Research (CBER). Raj also participated and supervised development of FDA policies and guidance documents for advanced therapies. He was also a Chief of Tumor Vaccines and Biotechnology Branch within DCGT and oversaw research programs of 13 Principal Investigators in DCGT. As a Principal Investigator and throughout his career, Raj has led research in the field of cancer research and discovery of novel immunotherapies. He has published more than 300 research and review articles, and participated in more than 220 speaking engagements at Scientific, Government, Industry and Professional Societies. Raj has been granted numerous patents on his discoveries and many of his patents are licensed for further developments. Raj has established seven Cooperative Research Development Agreements (CRADAs) with different companies to develop his discoveries for cancer therapy. Raj received numerous awards including FDA’s Award of Merit, FDA CBER’s Scientific Achievement Award, FDA Commissioner’s Special Citations and The SITC Collaborator Award. Raj trained at the National Cancer Institute’s Surgery Branch, where he worked in the laboratory of Dr. Steven Rosenberg on adoptive immunotherapy approaches for cancer. Raj was also trained at Mayo Clinic in Rochester, MN. He received his M.D. from the University of Juarez Medical School Institute of Biosciences and his Ph.D. in Medical Sciences from the Central Drug Research Institute, Lucknow.

Senior Vice President, Medical Affairs

Madan Jagasia, MD, MS, MHHC

Dr. Madan Jagasia joined Iovance in August 2020. He is an internationally recognized physician and clinical investigator with more than 25 years of clinical practice, including expertise in oncology and cell therapy. Prior to Iovance, Madan served as Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center at the Vanderbilt-Ingram Cancer Center (VICC) in Nashville, TN, a National Cancer Institute (NCI)-recognized Comprehensive Cancer Center. He also held roles as Co-leader, Translational Research and Interventional Oncology Research Program at VICC and Director, Stem Cell Transplant Program, Vanderbilt University Medical Center. In addition, Madan served as a Faculty Member, Division of Hematology-Oncology at Vanderbilt University Medical Center. Madan’s current and prior board and committee memberships include National Comprehensive Cancer Network (Board of Directors), GVHD (Graft Versus Host Disease) Committee for the Center of International Blood and Marrow Transplant Research (Co-Chair), and the Working Group on Early Diagnosis and Pre-emptive Therapy for the NIH Consensus Criteria for Chronic GVHD (Steering Committee Member and Co-Chair). He holds an M.S. in Clinical Investigation and a Master of Management in Health Care from Vanderbilt University, and a medical degree from King Edward Memorial Medical College (India). He has been an author on nearly 200 scientific publications, and participated in more than 100 speaking engagements at scientific and industry conferences.

Senior Vice President, Head of Digital and Information Technology

Brian Shew, MBA

Brian Shew joined Iovance in July 2021. He is a leader in information technology for global, publicly traded, expansion stage biopharmaceutical companies. He previously served as Chief Information Officer at Jazz Pharmaceuticals for 9 years where the company grew ten-fold to become a $2B+ revenue global multi-product commercial company. Earlier, he held IT roles of increasing responsibility at Codexis, CV Therapeutics (acquired by Gilead Sciences) and Genencor International. Brian received a B.S. in Biochemistry from the University of California, Davis, and an M.B.A. from Santa Clara University.

Senior Vice President, Quality

Kevin Smyth

Kevin Smyth joined Iovance in April 2018 and was appointed Senior Vice President, Quality in 2021. He has 30 years of experience in the pharmaceutical and biopharmaceutical industries. Previously he served as Vice President Regulatory, Quality, and Pharmacovigilance at PaxVax, a private-equity company that marketed nine vaccines for infectious diseases in 25 countries. While at PaxVax he was responsible for the BLA submission, priority review, and first-cycle approval of Vachora®. Earlier he held roles of increasing responsibility at Baxter International, including as regulatory lead responsible for the development and submission of global market applications for Rixubis® (U.S., EU, Japan), now marketed in over 40 countries. Kevin received a B.S. in Biochemistry from the University of Calgary and an M.S. in Toxicology from the Simon Fraser University.

Senior Vice President, Human Resources

Tracy Winton

Tracy Winton joined Iovance in April 2020. She has more than 30 years of cumulative leadership experience within the life sciences and high-tech industries. Most recently, she held multiple leadership roles at Nektar Therapeutics, culminating in Vice President, Human Resources. Her prior experience includes senior management roles at Sybase, Philips Semiconductors and Telecom New Zealand. Tracy has served as Board Member and Board Chair on several professional non-profits over the past 30 years. Tracy received a B.S. in Anatomy and Microbiology from the Otago University (New Zealand) and a Master of Business Studies (Human Resources) from the Massey University (New Zealand).

Senior Vice President, Research

Hequn Yin, PhD

Dr. Hequn Yin joined Iovance in November 2021. He is a pharmacologist by training with 25 years of discovery and development experience in various therapeutic areas within the biopharmaceutical industry. His prior leadership roles included Vice President of Oncology Research at Pfizer, Executive Director at Novartis, Chief Scientific Officer at Fosun Pharma, and President of Innovation Institute at Qilu Pharma. He has contributed to the development of widely used therapies during his career such as the cancer therapies Kymriah® (the first CAR-T therapy approved by U.S. FDA) and Affinitor®, as well as the autoimmune disease therapy Cosentyx®. Hequn earned a Ph.D. in Pharmacology from the University of Rochester and then conducted post-doctoral research in the Department of Biochemistry and Molecular Pharmacology at University of California, San Francisco.

Senior Vice President, Commercial

Jim Ziegler, MBA

Jim Ziegler joined Iovance in February 2020. He has more than 25 years of experience in leading or supporting over ten product launches during his career in the biopharmaceutical industry. Previously, he served in numerous commercial roles at Gilead Sciences during a 10-year period, most recently as Vice President, Cardiopulmonary and Inflammation Business Unit. At Gilead, he led the U.S. launch team for Gilead’s first oncology launch and supported the launch and access for several multi-billion-dollar antiviral products in HIV, HCV, and HBV. His earlier experience also includes commercial roles of increasing responsibility at Biogen, Amgen, and Pfizer. Prior to the biopharmaceutical industry, he served as an Armor Officer in the U.S. Army. Jim received a B.S. from the United States Military Academy at West Point, and an M.B.A. from The University of Chicago.